NCT05972135 2026-04-22
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
Clinical Trials
105 trialsNCT03412877 2026-04-20
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05909059 2026-04-20
CAR T-cell Therapy in Patients With Renal Dysfunction
Northside Hospital, Inc.
Phase 2 Recruiting
NCT05969860 2026-04-20
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06179888 2026-04-20
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06083922 2026-04-16
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05336383 2026-04-15
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07107529 2026-04-15
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
Phase 2 Recruiting
NCT06103838 2026-04-14
18F-Fluciclovine PET/CT in Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07382739 2026-04-14
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04634552 2026-04-13
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06483100 2026-04-13
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Washington University School of Medicine
Phase 2 Recruiting
NCT06500884 2026-04-13
Talisman
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07149857 2026-04-13
CARTITUDE-10
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07266441 2026-04-13
TRIlogy-3
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07509086 2026-04-03
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
The First Hospital of Jilin University
Phase 2 Recruiting
NCT02693535 2026-04-02
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT03297606 2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07489534 2026-03-24
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Chinese PLA General Hospital
Phase 2 Recruiting
NCT05405387 2026-03-20
IMPACT
University of Utah
Phase 2 Recruiting
NCT05272826 2026-03-18
BOREALIS
Canadian Myeloma Research Group
Phase 2 Recruiting
NCT06138275 2026-03-13
Elranatamab in R/R Multiple Myeloma
Massachusetts General Hospital
Phase 2 Recruiting
NCT06832865 2026-03-12
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
Phase 2 Recruiting
NCT07284758 2026-03-12
MOMENTUM
C4 Therapeutics, Inc.
Phase 2 Recruiting
NCT05896228 2026-03-11
Iber-KDd
University of Miami
Phase 2 Recruiting
NCT06976476 2026-03-11
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07454382 2026-03-06
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05091372 2026-03-05
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06066346 2026-03-04
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05344833 2026-02-23
HEME-18
University of Illinois at Chicago
Phase 2 Recruiting
NCT05530421 2026-02-23
SELVEDge
University of Miami
Phase 2 Recruiting
NCT06100237 2026-02-23
REVIVE
University of Miami
Phase 2 Recruiting
NCT06711705 2026-02-20
Elranatamab in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
Phase 2 Recruiting
NCT06207799 2026-02-19
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06679829 2026-02-19
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06015542 2026-02-10
ERICA
Odense University Hospital
Phase 2 Recruiting
NCT06297226 2026-02-10
QUINTESSENTIAL
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT06940297 2026-02-06
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Recruiting
NCT05847569 2026-02-03
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Recruiting
NCT04414475 2026-02-02
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Karyopharm Therapeutics Inc
Phase 2 Recruiting
NCT04240054 2026-01-28
VICD
Medical College of Wisconsin
Phase 2 Recruiting
NCT06974786 2026-01-23
FASTER
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT05922501 2026-01-14
ISABELA
Massachusetts General Hospital
Phase 2 Recruiting
NCT06627751 2026-01-12
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT05231629 2026-01-09
MASTER-2
University of Alabama at Birmingham
Phase 2 Recruiting
NCT06910124 2026-01-08
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
University of Miami
Phase 2 Recruiting
NCT04991103 2025-12-31
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
Phase 2 Recruiting
NCT07312188 2025-12-31
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Phase 2 Recruiting
NCT05695508 2025-12-24
HD10/DSMMXX
University of Heidelberg Medical Center
Phase 2 Recruiting
NCT05789303 2025-12-22
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
University of Chicago
Phase 2 Recruiting